Agapitov Alexei Vasilievich, Correia Marcelo Lima de Gusmão, Sinkey Christine Ann, Haynes William Geoffrey
Institute for Clinical and Translational Science, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Hypertension. 2008 Oct;52(4):687-95. doi: 10.1161/HYPERTENSIONAHA.107.109603. Epub 2008 Aug 11.
Obesity increases the risk of hypertension and its cardiovascular complications. This has been partly attributed to increased sympathetic nerve activity, as assessed by microneurography and catecholamine assays. However, increased vasoconstriction in response to obesity-induced sympathoactivation has not been unequivocally demonstrated in obese subjects without hypertension. We evaluated sympathetic alpha-adrenergic vascular tone in the forearm by brachial arterial infusion of the alpha-adrenoreceptor antagonist phentolamine (120 microg/min) in normotensive obese (daytime ambulatory arterial pressure: 123+/-1/77+/-1 mm Hg; body mass index: 35+/-1 kg/m(2)) and lean (daytime ambulatory arterial pressure: 123+/-2/77+/-2 mm Hg; body mass index: 22+/-1 kg/m(2)) subjects (n=25 per group) matched by blood pressure, age, and gender. Microneurographic sympathetic nerve activity to skeletal muscle was significantly higher in obese subjects (30+/-3 versus 22+/-1 bursts per minute; P=0.02). Surprisingly, complete alpha-adrenergic receptor blockade by phentolamine (at concentrations sufficient to completely inhibit norepinephrine and phenylephrine-induced vasoconstriction) caused equivalent vasodilatation in obese (-57+/-2%) and lean subjects (-57+/-3%; P=0.9). In conclusion, sympathetic vascular tone in the forearm circulation is not increased in obese normotensive subjects despite increased sympathetic outflow. Vasodilator factors or mechanisms occurring in obese normotensive subjects could oppose the vasoconstrictor actions of increased sympathoactivation. Our findings may help to explain why some obese subjects are protected from the development of hypertension.
肥胖会增加患高血压及其心血管并发症的风险。这部分归因于交感神经活动增加,这是通过微神经ography和儿茶酚胺测定来评估的。然而,在没有高血压的肥胖受试者中,肥胖诱导的交感神经激活引起的血管收缩增加尚未得到明确证实。我们通过在正常血压的肥胖(日间动态动脉压:123±1/77±1 mmHg;体重指数:35±1 kg/m²)和瘦(日间动态动脉压:123±2/77±2 mmHg;体重指数:22±1 kg/m²)受试者(每组n = 25)中经肱动脉输注α-肾上腺素能受体拮抗剂酚妥拉明(120 μg/min)来评估前臂的交感α-肾上腺素能血管张力,这些受试者在血压、年龄和性别方面相匹配。肥胖受试者中对骨骼肌的微神经graphic交感神经活动明显更高(每分钟30±3次爆发与22±1次爆发;P = 0.02)。令人惊讶的是,酚妥拉明(在足以完全抑制去甲肾上腺素和苯肾上腺素诱导的血管收缩的浓度下)对α-肾上腺素能受体的完全阻断在肥胖(-57±2%)和瘦受试者(-57±3%;P = 0.9)中引起了等效的血管舒张。总之,尽管交感神经流出增加,但正常血压肥胖受试者前臂循环中的交感血管张力并未增加。正常血压肥胖受试者中出现的血管舒张因子或机制可能会对抗交感神经激活增加的血管收缩作用。我们的发现可能有助于解释为什么一些肥胖受试者能够免受高血压的发展。